10-Q: Definitive Healthcare Corp. Reports Q1 2025 Results, Impacted by Goodwill Impairment and Revenue Decline

Definitive Healthcare Corp. reported a net loss of $155.1 million for Q1 2025, primarily due to a goodwill impairment charge and a decrease in revenue.

Summary

• Definitive Healthcare Corp. reported a net loss of $155.1 million for the first quarter ended March 31, 2025, compared to a net loss of $12.7 million for the same period in 2024.
• Revenue decreased by 7% to $59.2 million, driven by a decline in subscription revenue.
• The company recorded a goodwill impairment charge of $176.5 million due to a sustained decrease in its stock price.
• Operating expenses increased significantly due to the goodwill impairment, partially offset by decreases in sales and marketing, product development, and general and administrative expenses.
• The company amended its credit agreement, resulting in a $69.1 million repayment of the term loan and a $25.0 million reduction in the revolving credit facility.
• Definitive Healthcare repurchased 5.6 million shares of Class A Common Stock for $21.2 million during the quarter.
• The company's net dollar retention rate (NDR) is being monitored to measure growth from existing customers.
• Current remaining performance obligations (cRPO) were $181.8 million as of March 31, 2025.
• The company expects revenue to decline in 2025 compared to 2024.

Sentiment

Score: 3

Explanation: The document presents a negative outlook due to the significant net loss, revenue decline, and goodwill impairment. While the company is taking steps to manage expenses and invest in the future, the overall tone is concerning from an investment perspective.

Positives

• The company amended its credit agreement to improve its financial flexibility.
• Definitive Healthcare repurchased shares, indicating confidence in the company's long-term value.
• The company is taking steps to manage operating expenses, including restructuring efforts.
• The company is investing in new products and data sources to enhance its platform.

Negatives

• The company reported a significant net loss of $155.1 million in Q1 2025.
• Revenue decreased by 7% compared to the same period last year.
• A goodwill impairment charge of $176.5 million was recorded, reflecting a decline in the company's valuation.
• The company expects revenue to decline in 2025 compared to 2024.
• Customer churn has increased, particularly among smaller customers.

Risks

• Continued declines in market capitalization could lead to further goodwill impairments.
• Macroeconomic conditions could negatively impact customer spending and lengthen deal cycles.
• Changes in the healthcare claims data market could increase data acquisition costs.
• Sales execution challenges could continue to impact revenue growth.
• The company's ability to attract and retain customers is dependent on the strength of its platform and effectiveness of its go-to-market strategy.

Future Outlook

The company expects revenue to decline in 2025 compared to 2024 due to sales execution challenges, macroeconomic headwinds, and lower subscription renewals.

Management Comments

• The company is focused on managing operating expenses and investing in new products and data sources.
• The company is monitoring the net dollar retention rate (NDR) to measure growth from existing customers.
• The company is navigating macroeconomic challenges and their impact on customer spending.

Industry Context

The healthcare commercial intelligence market is competitive, and Definitive Healthcare faces competition from other providers of healthcare data and analytics. Macroeconomic conditions are impacting the broader SaaS industry, with companies experiencing longer sales cycles and increased customer churn.

Comparison to Industry Standards

• Given the goodwill impairment, Definitive Healthcare's performance lags behind industry leaders like Veeva Systems, which have demonstrated consistent revenue growth and profitability.
• Compared to peers like IQVIA, which also operate in the healthcare data and analytics space, Definitive Healthcare's revenue decline and net loss raise concerns about its competitive positioning.
• The company's net dollar retention rate (NDR) will be a key indicator of its ability to retain and expand its customer base, a metric closely watched by investors in the SaaS industry.
• The company's cRPO is lower than some industry benchmarks, indicating potential challenges in future revenue growth.

Management Changes

Related Party Transactions

• The Company has engaged in revenue transactions within the ordinary course of business with entities affiliated with its Sponsors and with members of the Company’s board of directors.
• During the three months ended March 31, 2025 and 2024 , the Company recorded revenue from related parties of $ 0.2 million and $ 0.4 million, respectively.
• Receivables for related party revenue transactions amounted to less than $ 0.1 million and $ 0.2 million at March 31, 2025 and December 31, 2024, respectively.
• During the three months ended March 31, 2025, the Company also paid $ 0.3 million to related parties for transactions within the ordinary course of business.

Stakeholder Impact

• Shareholders: The net loss and goodwill impairment will likely negatively impact shareholder value.
• Employees: Restructuring efforts may lead to job losses and uncertainty.
• Customers: The company's ability to invest in its platform and provide quality service could be affected.
• Creditors: The amended credit agreement provides some financial flexibility.

Next Steps

• The company will continue to monitor for potential impairment indicators.
• The company will focus on improving sales execution and customer retention.
• The company will continue to invest in new products and data sources.
• The company will manage operating expenses to improve profitability.

Key Dates

Keywords

Definitive Healthcare, financial results, goodwill impairment, revenue decline, Q1 2025, healthcare commercial intelligence, SaaS, net loss, stock repurchase, credit agreement, restructuring, market capitalization, customer churn